Division of Nephrology, Department of Medicine, Sydney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Department of Pathology, Sydney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
J Immunol Res. 2016;2016:5197396. doi: 10.1155/2016/5197396. Epub 2016 Dec 14.
Central to the humoral theory of transplantation is production of antibodies by the recipient against mismatched HLA antigens in the donor organ. Not all mismatches result in antibody production, however, and not all antibodies are pathogenic. Serologic HLA matching has been the standard for solid organ allocation algorithms in current use. Antibodies do not recognize whole HLA molecules but rather polymorphic residues on the surface, called epitopes, which may be shared by multiple serologic HLA antigens. Data are accumulating that epitope analysis may be a better way to determine organ compatibility as well as the potential immunogenicity of given HLA mismatches. Determination of the pathogenicity of alloantibodies is evolving. Potential features include antibody strength (as assessed by antibody titer or, more commonly and inappropriately, mean fluorescence intensity) and ability to fix complement ( by C1q or C3d assay or by IgG subclass analysis). Technical issues with the use of solid phase assays are also of prime importance, such as denaturation of HLA antigens and manufacturing and laboratory variability. Questions and controversies remain, and here we review new relevant data.
移植体液学说的核心是受者针对供者器官中不匹配的 HLA 抗原产生抗体。然而,并非所有不匹配都会导致抗体产生,也并非所有抗体都是致病性的。血清学 HLA 配型一直是当前使用的实体器官分配算法的标准。抗体不是识别整个 HLA 分子,而是识别表面的多态性残基,称为表位,这些表位可能与多个血清学 HLA 抗原共享。越来越多的数据表明,表位分析可能是一种更好的方法,可以确定器官相容性以及特定 HLA 不匹配的潜在免疫原性。同种异体抗体的致病性的确定正在发展中。潜在的特征包括抗体强度(通过抗体滴度评估,或者更常见和不恰当地通过平均荧光强度评估)和补体固定能力(通过 C1q 或 C3d 测定或 IgG 亚类分析评估)。使用固相测定法的技术问题也非常重要,例如 HLA 抗原的变性以及制造和实验室的变异性。仍存在一些问题和争议,我们在此回顾新的相关数据。